Table 1:

Baseline characteristics (n=391) and comparison to RESONATE-2 data (n=135)

Characteristic		Number with available data	RESONATE-2 published data
Median age at CLL diagnosis	63 years (32-96)	391	Not available / reported
Median age at ibrutinib start	68 years (36-96)	391	73 (65-89)
Median time from CLL diagnosis to ibrutinib start	31 months	388	31 months
Age <65 years at ibrutinib start	41%	391	0%
Male sex	62.4%	391	65%
Caucasian	92.4%	384	Not available
Rai stage 3-4	49.1%	383	44%
del(17p13) present	29.8%	369	0%
del(11q) present	17.1%	367	21%
TP53 mutation	20.1%	219	Not available / reported
del(17p13) and TP53 mutation (for patients who had both FISH and NGS testing)	16.0%	219	Not available / reported
Complex karyotype (≥ 3)	23.6%	279	Not available / reported
IGHV unmutated	67.4%	221	43%
β2 microglobulin above ULN	74.9%	146	62%
Elevated lactate dehydrogenase	49%	344	29%
Median follow up	13.8 months (1-76)	383	18.4 months